Actinium Pharmaceuticals has been granted a patent for humanized anti-human CD45 antibodies and pharmaceutical compositions. The patent includes specific sequences for the immunoglobulin heavy and light chain variable regions. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of May 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized anti-cd45 antibodies for pharmaceutical compositions
A recently granted patent (Publication Number: US11981741B2) discloses an invention related to anti-huCD45 antibodies or huCD45-binding antibody fragments. The claims of the patent detail specific sequences for the immunoglobulin heavy chain variable region and the immunoglobulin light chain variable region that are essential components of the antibodies. Additionally, the patent describes the composition of pharmaceutical and radiopharmaceutical compositions containing the antibodies or antibody fragments along with radionuclides and pharmaceutically acceptable excipients. The radiopharmaceutical compositions may include radionuclides such as 131I, 225Ac, 177Lu, or 90Y, which are alpha or beta particle emitters.
Furthermore, the patent covers compositions where the anti-huCD45 antibodies or antibody fragments are chemically conjugated to chelators, with specific mention of DOTA or DOTA derivatives as potential chelators. These compositions may also include radionuclides chelated by the chelator, expanding the potential applications of the invention in the field of targeted therapy and imaging. The detailed claims provide a roadmap for the development and utilization of these novel compositions in the medical field, particularly in the areas of cancer treatment and diagnostic imaging.
To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
